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Abstract 
Background: Uncertainty about cure puts childhood cancer survivors at risk of mental distress. 
We asked survivors if they had been told they had been cured and investigated associated factors. 
Procedure: We used nationwide registry data and a questionnaire survey for ≥5-year survivors 
of childhood cancer (n=301), followed by online focus groups with a purposive sample of Swiss 
pediatric oncologists (n=17). Discussions were coded by investigators using thematic analysis. 
Results: Overall, 235 among 301 survivors (78%, 95% confidence interval 73–83%) reported 
having been told they were cured. The proportion was 89% (81–97%) among lymphoma and 
84% (77–91%) among leukemia survivors, but only 49% (33–65%) among central nervous 
system tumor survivors. Pediatric oncologists acknowledged that telling survivors they are cured 
may reassure them that their cancer lies behind them. However, many refrained from telling all 
patients. Reasons included: the possibility of late effects (cure disrupted by a continued need for 
follow-up care) or late relapse (uncertainty of biological cure), case-by-case strategies (use of 
“cure” according to individual factors), and reluctance (substitution of noncommittal terms for 
“cure”; waiting for the patient to raise the topic). 
Conclusions: Not all physicians tell survivors they have been cured; their choices depend on the 
cancer type and risk of late effects. 
 
  
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
2
7
0
4
9
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
 
2 
 
Introduction 
More than 80% of childhood cancer patients 
currently survive at least 5 years after 
diagnosis.[1] Patients are transitioned to a 
survivorship clinic typically 1 to 5 years after 
treatment.[2] The word “cure” has a central 
meaning in this process: Besides its biological 
meaning (permanent remission), this term has 
also a psychosocial meaning (the belief one has 
left cancer behind).[3] While waiting to learn 
whether remission is permanent, patients must 
cope with uncertainty, which can cause mental 
distress.[4] For childhood cancer survivors, this 
fear of recurrence has been called ‘Damocles’ 
syndrome’.[5,6]  
In general, scientific studies do not mention cure 
but report survival and remission. Nevertheless, 
some studies have raised the concept of cure. 
Since the mid-20th century, the content of 
conversations on cure have evolved: the first 
success stories of chemo- and radiotherapy let 
physicians dream of a cure; later, those not 
believing in cures were to be condemned, and 
cure became a major goal (Supplementary 
Figure S1).[7,8] Cure has been defined as the 
recovery from the original cancer,[9,10] i.e., 
physicians discussing the cancer-related 
prognosis with children and parents as a 
likelihood or hope of cure.[10,11] 
As stated in the Erice statement, written by 
physicians, survivors, psychologists, nurses and 
epidemiologists in 2007 and updated in 2018, 
pediatric oncologists can use the term “cure” in 
discussions with childhood cancer survivors 
regardless of remaining uncertainty caused by 
the type of cancer they had, or existing or 
potential late effects of treatment.[12,13] This 
uncertainty includes some remaining risk of 
relapse, but also excess morbidity and 
death.[14,15] Late effects can begin decades 
after the end of treatment and include physical 
[16,17] or psychological and social 
problems.[18,19] By age 50, 96% of childhood 
cancer survivors have had a severe to life-
threatening chronic condition.[20] Reassuring 
cancer patients they are cured while making sure 
they understand the need to continue follow-up 
care because of the potential for late effects is a 
delicate balance. 
It is unclear whether pediatricians commonly tell 
childhood cancer survivors they are cured. To 
find out, we undertook a mixed-methods study.  
 
Methods 
Study design 
We followed a sequential explanatory study 
design (Supplementary Figure S2) that used 
quantitative methods followed by qualitative 
methods.[21] We first conducted a quantitative 
analysis to determine the proportion of 
childhood cancer survivors who are told by their 
physicians that they have been cured, and which 
factors determine whether this is done. We then 
conducted a qualitative analysis to examine the 
underlying reasons and the experiences of 
physicians in detail. To do so, we combined 
registry data and closed-ended questions in a 
questionnaire to survivors with online focus 
group online focus group discussions among 
pediatric oncologists. 
 
Quantitative methods 
Study population 
Since 1976, the Swiss Childhood Cancer 
Registry (SCCR) has collected data on all 
children in Switzerland diagnosed with 
leukemia, lymphoma, central nervous system 
(CNS) tumors, malignant solid tumors, or 
Langerhans cell histiocytosis.[22] The Swiss 
Childhood Cancer Survivor Study (SCCSS) is a 
questionnaire study of all 5-year survivors which 
includes baseline and follow-up questionnaires. 
The follow-up questionnaire was sent to a 
subsample 3 years after the baseline 
questionnaire.[23] Eligibility criteria for the 
follow-up questionnaire were: diagnosis of 
childhood cancer in Switzerland after 1990, <16 
years of age at diagnosis, having survived ≥5 
years after diagnosis, >18 years of age at the 
time of the study, and having replied to the 
baseline questionnaire. Eligible survivors 
received the questionnaire with a prepaid return 
envelope. Non-responders received a second 
questionnaire two months later. The 
questionnaire was available in German and 
French. 
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The outcome of interest  
The follow-up questionnaire contained the 
question: “Have you ever been told you were 
cured?” Respondents who said yes were then 
asked who told them and when. 
 
Explanatory factors 
We sought to determine which of the following 
explanatory factors were associated with the 
message of cure: age at survey, age at diagnosis, 
year of diagnosis, sex, language region (German, 
French/Italian), type of cancer (according to the 
International Classification of Childhood 
Cancer, 3rd Edition),[24] radiotherapy (no 
radiotherapy, body and limb irradiation, cranio-
spinal irradiation), relapse of original cancer 
(no/yes), and type of clinic (university or 
regional clinic). Information on those factors 
came from the registry. In addition, we used data 
from the SCCSS baseline questionnaire: 
presence of late effects (self-reported; no/yes) 
and migration background (those without Swiss 
citizenship since birth, not born in Switzerland, 
or having at least one non-Swiss citizen parent; 
no/yes), and from the SCCSS follow-up 
questionnaire: education (primary [compulsory 
schooling only]; secondary [including vocational 
training, teachers’, technical and commercial 
schools]; and tertiary [including university and 
university of applied sciences]). 
 
Analysis 
We determined the proportions of survivors 
described as “cured” and stratified by all listed 
explanatory factors. We compared the 
proportions using Chi-squared tests. Reporting 
of the quantitative part of this study follows 
STROBE guidelines (Supplementary Document 
2). 
Since 2004, all patients and their families give 
informed consent at the time of cancer diagnosis 
for their data to be included in the SCCR and 
used for research. Patients who had been 
diagnosed in the early years of the registry 
received the information retrospectively and 
could object to their inclusion in the registry 
(right of veto). This procedure was decided by 
the Swiss Federal Commission of Experts for 
Professional Secrecy in Medical Research when 
granting the general cancer registry permission 
to the SCCR, and was endorsed by the ethics 
committee of the canton of Bern (KEK-BE: 
166/2014). 
 
Qualitative methods 
Source of data 
We conducted online focus groups to which we 
invited all pediatric oncologists in Switzerland. 
Using the official online directory of physicians 
in Switzerland (http://www.doctorfmh.ch/), we 
retrieved information on their medical specialty, 
preferred language, and year of graduation from 
medical school and sent them an e-mail with a 
short description of the study and a link to an 
internet forum where the online focus groups 
took place.  
The forum was developed by the Netherlands 
Institute for Health Services Research in 
Utrecht. It allowed asynchronous discussions, 
i.e. reading and writing of contributions at any 
time, 24 hours a day, for a period of one month. 
Each participant and the moderator (S.E.) 
received a unique login name and password to 
access the forum. The confidentiality of 
contributions was secured by anonymized login 
names and SSL cryptography. Using a 
homogenous, purposive sampling technique, we 
split the physicians into two German-speaking 
forums according to their year of graduation 
(before 1991 and from 1991 onward).[25,26] We 
conducted an online focus group with physicians 
in the French- and Italian-speaking part of 
Switzerland, but only three participated. 
Therefore, we considered their discussion 
unrepresentative. We provide the anonymized 
transcript of this online focus group in 
Supplementary Document 3. 
 
Data of interest 
Physicians were asked to study the main result 
of the quantitative analysis provided in the 
forum (proportion of survivors who were told 
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they had been cured; overall and by diagnostic 
groups). In the main thread of the forum, they 
were encouraged to comment on these data, 
react to each other’s contributions, and suggest 
what might explain why a childhood cancer 
survivor was or was not told he or she was 
cured. Two marginal threads were available to 
initiate discussions, share examples of 
conversations about cure, and mention published 
or institutional guidelines or statements on 
communicating cure, including the Erice 
statement.[13] In this study, we did not 
differentiate between the three threads, as many 
physicians submitted all their contributions in 
only one of the threads. The moderator 
interacted with participants, by asking follow-up 
questions and clarifying participants’ views. 
 
Analysis 
We interpreted the physicians’ answers using a 
thematic analysis framework: Coding the text 
was a hybrid of a deductive a priori template of 
codes (from quantitative results) and data-driven 
inductive codes (adding new/explaining 
factors).[27] Two investigators (S.E. and C.D.) 
coded the transcripts independently. In 
discussions, disagreements were resolved, and 
data categorized into themes. Discussions of 
online focus groups were copied verbatim from 
the forum, and S.E. and C.D. translated them 
from German to English. An interpreter 
independently checked the translations for 
accuracy. Direct quotations give evidence of 
both typical views and of the diversity of views 
obtained. 
All participants in the online focus group 
discussions agreed to take part in the study. A 
jurisdictional inquiry to the ethics committee 
confirmed their non-involvement as the need to 
obtain formal approval was waived. 
 
Results 
Information from survivors (quantitative data) 
Of 754 eligible childhood cancer survivors, 710 
could be contacted and 322 (45%) returned the 
follow-up questionnaire (Figure 1). Average age 
of participants was 9 years at diagnosis and 21 
years at the time of the survey (Table 1). 
Compared with non-participants, more 
participants were female (57 vs. 42%) and 
reported suffering from late effects (42 vs. 34%). 
Seventy-eight percent (235/301, 95% confidence 
interval 73 to 83%) reported that they had been 
told they were cured. This differed by diagnosis 
and was 89% (81–97%) in lymphoma survivors, 
84% (77–91%) in leukemia survivors, 76% (58–
94%) in renal tumor survivors, 67% (48–86%) in 
bone tumor survivors, and 49% (33–65%) in 
CNS tumor survivors (Table 2). Survivors who 
had been given the message of cure were 
generally younger at diagnosis, further from 
diagnosis, French- or Italian-speaking, had 
experienced no relapse, and had secondary 
education. Year of diagnosis, sex, radiotherapy, 
type of clinic, presence of late effects, and 
migration background were not associated with 
the message of cure. Survivors had received the 
message of cure a median 6 years after diagnosis 
(interquartile range 5–8 years, overall range 0–
16 years). 
 
Information from physicians (qualitative data) 
Of 51 (37 German-speaking) eligible physicians, 
42 (31) could be contacted and 20 (17) 
participated (Figure 2). More participants were 
male compared with non-participants (65% vs. 
50%); there was no difference in age. 
The participating physicians highlighted the 
following objective and subjective factors to 
explain which survivors had been told they were 
cured. These factors are summarized here, and 
additional points can be found in Supplementary 
Document 4. Published statements on 
communicating cure, including the Erice 
statement, and guidelines were widely unknown 
to the pediatric oncologists, and therefore did not 
explain why certain survivors had been told they 
were cured. 
Helping survivors finish the cancer story – All 
pediatric oncologists acknowledged that telling 
survivors that they are cured may help them 
“finish the cancer story”. Some suggested that 
the message of cure can lower the level of 
anxiety in survivors. Having been cured was 
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viewed as patients’ goal and motivation for 
undergoing taxing therapy (quotations in 
Supplementary Document 5). No participant 
mentioned that the message had a negative effect 
or had to be reconsidered later. 
Late effects – Many physicians did not tell all 
survivors that they had been cured because of 
existing or potential late effects, especially when 
these effects were severe. They also feared that 
patients who were told they were cured could 
have less understanding of the need for 
continued follow-up care. As a divergent view, 
one physician told survivors about cure 
irrespective of late effects. 
Late relapse – The diminishing risk of relapse 
was an important factor for using the term 
“cure”. Sometimes, the opposite was true: 
Physicians did not talk about cure because they 
wanted to be honest when considering the small 
long-term risk of a recurrence. 
Case-by-case use – Some physicians said that 
they followed a case-by-case approach, using the 
term “cure” depending on individual factors 
related to patients and environment. These 
factors included, for instance, the type of disease 
and parents’ communication style. One 
physician mentioned that this complexity 
renders any communication guidelines useless. 
Reluctance – Many physicians were reluctant to 
use the term “cure” and so used noncommittal 
terms and expressions, waiting until patients 
specifically raised the topic. Two physicians 
remained passive and assumed that an early 
discussion of cure, e.g. during treatment, would 
be sufficient and remembered by patients and 
their relatives later on. Some physicians did not 
exhibit reluctance around the term and actively 
used it because they felt it was expected by 
survivors and parents. 
Helping physicians resolve cognitive dissonance 
– One important underlying reason for 
physician’s communication choices was not 
based on patients’ needs. Instead, some 
physicians  resolved their own cognitive 
dissonance between wanting to help patients and 
their families get past the illness and wanting to 
be scientifically correct, i.e., acknowledging that 
the risk of relapse, secondary tumors or late 
effects remains present lifelong, even if it 
becomes smaller as time passes. 
 
Discussion 
We found that three-quarters of survivors had 
been told they had been cured. The questionnaire 
study showed an association of communicating 
cure with cancer type, younger age at diagnosis, 
longer time since diagnosis, language region, no 
relapse, and secondary education. Online focus 
group discussions among physicians explored 
underlying factors to be late effects, late relapse, 
case-by-case decision making, and reluctance to 
use the term cure. 
We combined a quantitative and a qualitative 
approach to account for the complexity of the 
topic, following the advice that different 
methods employed should allow different 
insights to tell the reader something new.[28] 
Focus groups were particularly suited for 
studying physicians’ attitudes and experiences in 
terms of communicating cure. They allowed a 
shift from personal, self-centered explanations to 
structural ones, e.g. most participants did not use 
“I”-statements, but instead discussed why 
“pediatric oncologists” used the term cure. The 
group setting might have helped those who felt 
they had nothing to say to engage in discussions 
generated by the moderator and other 
participants.  
The use of asynchronous online focus groups 
had some distinct advantages compared with 
face-to-face focus groups. [29] First, this 
approach reached pediatric oncologists who 
have little spare time, and for this reason are 
often unwilling to travel to attend a face-to-face 
focus group. [30,31] Second, online focus 
groups allow participants time to elaborate their 
contribution before submitting it. This helps 
avoiding impulsive responses which may block 
the discussion. Furthermore, the virtual 
anonymous setting allowed participants to freely 
express their opinion without feeling judged. We 
carefully employed the thematic analysis to 
avoid de-contextualization of physicians’ words.  
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Only one former study empirically studied the 
actual use of the term cure in practice.[24] 
Miller reported that 81% of adult oncology 
clinicians in Boston (physicians, nurse 
practitioners, physician’s assistants) were 
hesitant to tell patients they had been cured, 
similar to our findings among Swiss pediatric 
oncologists. Furthermore, in Miller’s study, 
clinicians reported that patients were hesitant to 
ask whether they were cured.[24] We did not 
assess this question, but our finding that 
physicians are sometime reluctant to speak about 
cure would be of particular importance in a 
context where patients have to raise this topic 
themselves. A study with survivors of adolescent 
and young adult cancer showed that the fear of 
recurrence is highly prevalent in this population; 
the authors suggest the identification of 
underlying communication processes.[4] Sharing 
with these patients that they are considered 
cured may help address this fear. 
Pediatric oncologists might have passed the 
“peak” of believing in and communicating cure, 
because their knowledge of the late effects of 
treatment [16,17,32] and late recurrence of the 
original cancer [15,33] has increased over the 
last decades. Among other underlying reasons, 
late effects were cited in the current study by 
physicians who did not tell survivors that they 
have been cured, especially younger physicians. 
This could explain why those diagnosed after 
1995 were less likely to receive the message of 
cure than those diagnosed before. In general, 
younger physicians were more elaborate in their 
contributions of different underlying reasons, in 
contrast to clear cut views of older physicians. 
This could be related to inexperienced 
physicians who discuss “how it could/should be” 
and experienced physicians who convey their 
way of communicating cure. 
Pediatric oncologists might also lack the 
necessary skills to communicate cure. Adequate 
communication skills are a fundamental 
capability of physicians in oncology, but other 
studies have detailed the struggle of physicians 
with difficult communication tasks in 
general,[34,35] for instance with explaining 
randomization in childhood cancer trials [36] 
and cross-cultural negotiations.[37]  
Our results can inform communication strategies 
of health care professionals. Long-term follow-
up care provides regular opportunities for 
conversations on cure. Physicians might benefit 
from regular team discussions on cure, as one 
participant suggested, that prepare for the 
discussion with the survivor. Additionally, 
essential skills for communicating cure might be 
trainable. However, results from online focus 
groups also indicate that conversations on cure 
are complex. Furthermore, the Erice statement, 
promoting the message of cure,[12] was widely 
unknown to the pediatric oncologists in the 
online focus groups. For all these reasons, the 
role of statements and guidelines remains 
unclear and their further development would be 
challenging. 
Our study cannot represent all of the intricacies 
of physicians’ communication of cure. In 
particular, the closed-ended question assessing 
the message of cure is a simplification and 
cannot replace more in-depth studies. Some 
survivors were probably told they were cured 
but did not remember being told this. This could 
be for many reasons – the oncologist used 
another wording, the patient simply forgot, or 
other reasons. However, survivors who 
remembered having been told by a physician 
that they were cured had, on average, been 
diagnosed at earlier dates and at a younger age 
than those who did not. The participation rate of 
survivors was low; however, the sample 
appeared to be fairly representative, with the 
exception that responders were more likely to be 
female and have prevalent self-assessed late 
effects. This study was performed with survivors 
and physicians in Switzerland; results might 
differ in other countries. 
Providing the quantitative results from the 
survivors to the physicians rather than simply 
discussing about the concept of communicating 
cure to survivors might have biased the results. 
Only a few physicians did not contribute their 
own ideas, limiting themselves to agreeing with 
previous contributions. Unfortunately, we could 
only include German-speaking physicians in the 
analysis; there might have been cultural reasons 
for the low number of French-speaking 
physicians participating in the online focus 
groups. 
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We suggest evaluating survivors’ views and 
expectations on what kind of communication 
about cure suits them best. It is unclear if late 
effects should be considered when discussing 
cure. Telling a patient after the end of treatment 
that he or she has been cured might be a 
fundamental step to reduce emotional distress 
allowing survivors to achieve well-being, which 
is an important pillar of future cancer care.[38] 
Adequately powered studies should adjust for 
confounding in a multivariable analysis 
clarifying potential risk factors for not receiving 
the message of cure. The degree of emotional 
distress among childhood cancer survivors 
should be further studied. As far as we know, the 
link between not communicating cure and 
mental distress – for example, due to fear of 
recurrence – seems plausible, but has never been 
investigated. In this context, it will be important 
to use valid instruments to assess the 
outcome.[39,40] If the link is confirmed, it 
might be advisable to compare the effectiveness 
of a simple communication of cure with more 
complex strategies, such as psychological 
counseling, in designing interventions. 
In conclusion, we unfolded some of the 
biological and psychological motivations behind 
individual styles of communicating cure. The 
proportion of patients who had been told they 
were cured depended on the type of cancer, 
likelihood of late effects and on the attitude of 
the physicians towards the concept of cure. 
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TABLE 1 Characteristics of questionnaire non-participants and participants. Values are numbers (percentages) 
Characteristic Participants 
(n=301) 
Non-participants 
(n=409) 
p 
Age at time of study (years) 
- <25 
 
179 (59) 
 
233 (57) 
.538 
Age at diagnosis (years) 
- <5 
- 5-9 
- ≥10 
 
72 (24) 
90 (30) 
139 (46) 
 
106 (26) 
130 (32) 
172 (42) 
.732 
Year of diagnosis 
- <1995 
 
141 (47) 
 
204 (50) 
.447 
Sex 
- Men 
 
130 (43) 
 
236 (58) 
<.001 
Language region 
- German 
 
226 (75) 
 
305 (75) 
.877 
Type of cancer 
- Leukemia 
- Lymphoma 
- CNS tumor 
- Renal tumor 
- Bone tumor 
- Langerhans cell histiocytosis 
- Other types 
 
105 (35) 
56 (19) 
37 (12) 
21 (7) 
21 (7) 
13 (4) 
48 (16) 
 
131 (32) 
84 (20) 
64 (16) 
19 (5) 
24 (6) 
20 (5) 
67 (16) 
.639 
Radiotherapy 
- No radiotherapy 
- Body and limp irradiation 
- Cranio-spinal irradiation 
 
182 (60) 
73 (24) 
46 (15) 
 
260 (64) 
84 (21) 
65 (15) 
.244 
History of relapse 
- Yes 
 
35 (12) 
 
37 (9) 
.260 
Type of treatment clinic 
- University clinic 
- Regional clinic 
 
226 (75) 
75 (25) 
 
294 (72) 
115 (28) 
.590 
Prevalent late effects (self-assessed) 
- Yes 
 
124 (42) 
 
132 (34) 
.028 
Migration background 
- Yes 
 
24 (8) 
 
38 (9) 
.535 
Education 
- Primary 
- Secondary 
- Tertiary 
 
63 (21) 
165 (56) 
67 (23) 
 
77 (19) 
269 (66) 
63 (15) 
.190 
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TABLE 2 Proportion of survivors reporting that they were told that they had been cured, by 
sociodemographic and clinical characteristics 
Characteristic N % 95% CIa p 
Overall 235 78 73-83  
Age at study (years) 
- <25 
- ≥25 
 
138 
97 
 
77 
79 
 
71-83 
72-86 
.379 
Age at diagnosis (years) 
- <5 
- 5-9 
- ≥10 
 
59 
71 
103 
 
81 
79 
74 
 
72-90 
71-87 
67-81 
.048 
Year of diagnosis 
- <1995 
- ≥1995 
 
114 
119 
 
81 
74 
 
75-88 
67-81 
.050 
Sex 
- Men 
- Women 
 
101 
134 
 
78 
78 
 
71-85 
72-84 
.889 
Language region 
- German 
- French/Italian 
 
167 
68 
 
74 
91 
 
68-80 
85-97 
.002 
Type of cancer 
- Leukemia 
- Lymphoma 
- CNS tumor 
- Renal tumor 
- Bone tumor 
- Langerhans cell histiocytosis 
- Other types 
 
88 
50 
18 
16 
14 
12 
37 
 
84 
89 
49 
76 
67 
92 
77 
 
77-91 
81-97 
33-65 
58-94 
48-86 
77-107 
66-90 
<.001 
Radiotherapy 
- No radiotherapy 
- Body and limb irradiation 
- Cranio-spinal irradiation 
 
147 
56 
32 
 
81 
77 
70 
 
75-87 
67-85 
57-83 
.247 
History of relapse 
- No 
- Yes 
 
214 
21 
 
80 
60 
 
75-85 
44-75 
.006 
Type of treatment clinic 
- University clinic 
- Regional clinic 
 
178 
57 
 
79 
76 
 
73-85 
66-86 
.617 
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Prevalent late effects (self-assessed) 
- No 
- Yes 
 
141 
92 
 
82 
74 
 
76-88 
66-82 
.131 
Migration background 
- No (Swiss) 
- Yes 
 
216 
18 
 
78 
75 
 
73-83 
58-92 
.711 
Education 
- Primary 
- Secondary 
- Tertiary 
 
43 
137 
50 
 
68 
83 
74 
 
52-84 
76-90 
59-89 
.042 
a95% Confidence Interval 
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FIGURE 1 Participants in the Swiss Childhood Cancer Survivor Study 
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 FIGURE 2 Participants in the online focus groups 
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Supplementary Document 2: STROBE Statement — checklist 
 
 Item 
No Recommendation 
Reported on 
manuscript 
page 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term 
in the title or the abstract 
1 
(b) Provide in the abstract an informative and balanced 
summary of what was done and what was found 
2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported 
2 
Objectives 3 State specific objectives, including any prespecified 
hypotheses 
4 
Methods  
Study design 4 Present key elements of study design early in the paper 4 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data 
collection 
4 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the 
sources and methods of selection of participants. Describe 
methods of follow-up 
Case-control study—Give the eligibility criteria, and the 
sources and methods of case ascertainment and control 
selection. Give the rationale for the choice of cases and 
controls 
Cross-sectional study—Give the eligibility criteria, and the 
sources and methods of selection of participants 
4 
(b) Cohort study—For matched studies, give matching 
criteria and number of exposed and unexposed 
Case-control study—For matched studies, give matching 
criteria and the number of controls per case 
- 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, 
if applicable 
5 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and 
details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than 
one group 
6 
Bias 9 Describe any efforts to address potential sources of bias 6 
Study size 10 Explain how the study size was arrived at 8 
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Quantitative variables 11 Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were 
chosen and why 
6 
Statistical methods 12 (a) Describe all statistical methods, including those used to 
control for confounding 
6 
(b) Describe any methods used to examine subgroups and 
interactions 
- 
(c) Explain how missing data were addressed - 
(d) Cohort study—If applicable, explain how loss to follow-
up was addressed 
Case-control study—If applicable, explain how matching of 
cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical 
methods taking account of sampling strategy 
- 
(e) Describe any sensitivity analyses - 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-
up, and analysed 
8 
(b) Give reasons for non-participation at each stage 8 
(c) Consider use of a flow diagram Figure 2 
Descriptive data 14* (a) Give characteristics of study participants (eg 
demographic, clinical, social) and information on exposures 
and potential confounders 
Table 1 
(b) Indicate number of participants with missing data for 
each variable of interest Table 1 
(c) Cohort study—Summarise follow-up time (eg, average 
and total amount) - 
Outcome data 15* Cohort study—Report numbers of outcome events or 
summary measures over time 9 
Case-control study—Report numbers in each exposure 
category, or summary measures of exposure - 
Cross-sectional study—Report numbers of outcome events 
or summary measures - 
Main results 16 (a) Give unadjusted estimates and, if applicable, 
confounder-adjusted estimates and their precision (eg, 95% 
confidence interval). Make clear which confounders were 
adjusted for and why they were included 
9 
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(b) Report category boundaries when continuous variables 
were categorized - 
(c) If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period - 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses - 
Discussion  
Key results 18 Summarise key results with reference to study objectives 11 
Limitations 19 Discuss limitations of the study, taking into account sources 
of potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias 
12 
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
14 
Generalisability 21 Discuss the generalisability (external validity) of the study 
results 13 
Other information  
Funding 22 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on 
which the present article is based 
15 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and 
unexposed groups in cohort and cross-sectional studies. 
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Supplementary Document 3: Transcript of French-speaking online focus group 
 
a) Original 
 
Forum thread A 
Premier sujet: Souvenirs de conversations au sujet de la guérison 
Vous avez tous acquis une formation spécialisée en oncologie pédiatrique. Une conversation 
particulière entre vous et un patient(e) ou les parents de celui-ci (celle-ci) concernant la « 
guérison du cancer » vous est-elle restée en mémoire ? Veuillez s’il vous plaît nous décrire cette 
conversation. Pour quelle raison pensez-vous que cette conversation vous soit restée ? Deux 
remarques : vous pouvez sans autre intervenir pour d’autres conversations et discuter de la 
situation. Vous pouvez également nous faire part de plusieurs situations. 
 
Participant Physician #F1: 
Ces discussions sur le thème de la guérison sont certainement moins fréquentes et standardisées 
que les discussions "obligatoires" elles sur le diagnostic et le traitement, au moment de la 
découverte de la maladie. 
Je me souviens de plusieurs d'entre elles chez des patients avec LLA ou Hodkgin ou NHL, où le 
mot "guérison" ou la phrase "maintenant on peut considérer que tu es guéri(e)" a été utilisé. J'ai 
ensuite toujours précisé qu'il s'agissait là de la guérison oncologique ("le cancer ne va plus 
revenir") et qu'on a parlé ensuite des effets à long-terme possibles, y.c. les 2e cancers, surtout 
dans la maladie de Hodgkin (cancer du sein surtout, évent. de la thyroïde) et des mesures de 
dépistage précoce, même s'il reste des débats à ce sujet (quelle est la meilleure méthode pour le 
dépistage précoce, p.ex.) 
Ces discussions me sont restées, car elles montrent qu'au fond, pour ces patients-là, l'histoire 
n'est pas vraiment terminée, même s'ils sont oncologiquement guéris, sont parvenus à l'âge adulte 
et ne viendront plus en consultation chez nous. 
 
Modératrice: 
Traduction: 
Je n'ai aucun souvenir d'une conversation en particuler. J'ai pris notes de toutes les discussions 
auxquelles j'ai participé. 
 
Participant Physician #F2: 
Nessun ricordo di una conversazione in particolare. Di ogni conversazione alla quale ho assistito 
ho tratto degli spunti 
 
Forum thread B 
Deuxième sujet: Fréquence et moment du faire part de la guérison  
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Veuillez considérez les informations de fond (bouton). 
Comment interprétez-vous ces informations ? Quelles sont, selon vous, les raisons qui poussent 
un oncologue pédiatre à annoncer au patient qu’il est guéri ? Quelles sont, selon vous, les raisons 
qui poussent un oncologue pédiatre à ne pas annoncer au patient qu’il est guéri ? 
 
Participant Physician #F3 
La question ne peut pas se répondre en 5min par écrit. En résumé, tout dépends de la pathologie 
sous jacente et de quels tratement l'enfant a reu. En fonctions de cela, l'enfant pourrait être guéri  
mais avec des toxicité donc guérisson??? Les effets secondaire peuvent encore survenir plus tard, 
deuxième cancer....  
 
 
Participant Physician #F1 
Fréquence : comme je le disais en discutant la question 1, le thème de la guérison est abordé 
moins systématiquement; je dirais dans env. 50% des cas. On sait que c'est un thème difficile, 
des rechutes tardives (jusqu'à 10 ans post-Dx initial) sont théoriquement toujours possibles, donc 
le médecin a une certaine retenue. On hésite, on ne veut pas se faire traiter de menteur par son 
patient plus tard. 
Il est clair qu'il est plus facile (plus sûr) de parler de guérison dans certains diagnostics : 
Hodgkin, Burkitt, tumeur cérébrale bénigne opérée (ex. astrocytome pilocytique de la fosse 
postérieure) que dans d'autres (tumeur cérébrale maligne, neuroblastome métastatique, autres 
tumeurs métastatiques, etc.). Si le risque d'avoir des effets tardifs est grand (p.e.x 
médulloblastome), le médecin aura aussi moins tendance à parler de guérison que s'il est failble 
(LLA). 
Le moment de l'annonce d'une guérison se situe qq part entre 5 et 10 ans après le Dx initial, ceci 
peut varier en fonction de celui-ci et de certains autres facteurs, également selon la "psychologie" 
du patient ou des ses parents et de la relation construite au cours des années entre le médecin et 
son malade/sa famille. 
 
Modératrice: 
Traduction 
"Ce n'est pas un cas qu'on attend plus de 5 ans pour dire à un patient s'il est guéri. La plupart de 
rechutes surviennent durant cette période. Normalment on a aussi plus de rechutes pour les 
tumeur du système nerveux. Dans les cas pour lesquelles le prognostic est plus pessimiste 
(tumeur du système nerveux, sarcomes) on ne communique si fréquemment la guérison. 
 
 
Participant Physician #F2: 
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Non stupisce il fatto che in media si aspetti più di 5 anni per dire al paziente che é guarito. Di 
solito la maggior parte delle recidive avviene in questo periodo. Normale anche che nei tumori 
del SNC vi é più reticenza. 
In casi dove la prognosi é più incerta (tumori cerebrali, sarcomi) é possibile che si sia meno 
propensi a dare la notizia di guarigione. 
 
Forum thread C 
Troisième sujet : Directives pour la communication de la guérison 
Est-ce que vous connaissez des directives (provenant d’une clinique, de votre formation continue 
ou de publications) concernant le faire part d’une guérison ? Est-ce que vous vous y tenez ? Si 
oui, pourquoi ? Si non, pourquoi pas ? 
 
Participant Physician #F3: 
Non je ne connais pas de directives dans ce domaine. Je ne penses pas que cela soit très utile d'en 
avoir. A mon sesn le plus important est que les médecins aient une excellenet formation dans 
l'annonce des nouvelles, l'empathies. 
 
Participant Physician #F1: 
Je n'en connais pas non plus et je pense que c'est impossible et probablement inutile d'en 
produire. Pour le malade et sa famille, cette annonce d'une guérison de la maladie est 
certainement importante et très attendue; d'autre part, eux-mêmes savent souvent très bien qu'il 
ne s'agit souvent pas d'une guérison complète et qu'un suivi sera nécessaire, parfois toute la vie. 
Pour le médecin, parler de guérison, c'est prendre un risque : celui de se tromper ou d'induire en 
erreur son patient, ce qui est évidemment difficile à vivre. Donc, on hésite souvent. 
L'important, c'est le dialogue ouvert et le plus clair possible. Annoncer la guérison du cancer, 
oui, très probable, après une dizaine d'années sans rechute; mais avoir le courage aussi de parler 
d'effets à long-terme potentiels, de recommander un suivi lorsque c'est nécessaire et ici, suivre 
les recommandations existantes. En fait, continuer la stratégie bien connue en oncologie de 
l'information ouverte, du consentement éclairé (ici au suivi à long-terme quand il est nécessaire 
ou recommandé). 
 
Modératrice: 
Traduction du participant Physician #F2 
Je ne connais aucune directive pour communiquer la guérison à un patient. 
 
Participant Physician #F2: 
Non sono a conoscenza di direttive che indichino come informare un paziente sul fatto di essere 
guarito. 
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b) English 
 
Forum thread A 
First Topic: Memories of conversations about healing 
You all have specialized training in pediatric oncology. Is there a special conversation between 
you and a patient or his / her parents about the "cancer cure" in your memory? Please describe 
this conversation to us. Why do you think this conversation has stayed with you? Two remarks: 
you can not intervene for other conversations and discuss the situation. You can also tell us about 
several situations. 
 
Participant Physician #F1: 
These discussions on the theme of healing are certainly less frequent and standardized than the 
"mandatory" discussions on diagnosis and treatment at the time of the discovery of the disease. 
I remember several of them with patients with LLA or Hodkgin's or NHL, where the word "cure" 
or the phrase "now we can consider that you are cured" has been used. I always said that this was 
the oncological cure ("the cancer will not come back") and then we talked about possible long-
term effects, including 2nd cancers, especially in Hodgkin's disease (especially breast cancer, 
thyroid event) and early detection measures, although there is still debate about it (e.g. what is 
the best method for early detection) 
These discussions have stayed with me, because they show that basically, for these patients, the 
story is not really over, even if they are oncologically cured, have reached adulthood and will not 
consult with us anymore. 
 
 
Moderator: 
Translation: 
I have no memory of a particular conversation. I took notes of all the discussions I participated 
in. 
 
Participant Physician #F2: 
Nessun ricordo di una conversazione in particolare. Di ogni conversazione alla quale ho assistito 
ho tratto degli spunti 
 
Forum thread B 
Second topic: Frequency and timing of sharing healing  
 
23 
 
Please consider the background information (button). 
How do you interpret this information? What do you think are the reasons for a pediatric 
oncologist to tell the patient that he is cured? What do you think are the reasons for a pediatric 
oncologist not to tell the patient that he is cured? 
 
Participant Physician #F3 
The question can not be answered in 5 minutes in writing. In summary, everything depends on 
the underlying pathology and what treatment the child received. In these terms, the child could 
be cured but with toxicities, so cured??? Side effects may still occur later, a second cancer.... 
 
 
Participant Physician #F1 
Frequency: As I said while discussing Question 1, the theme of healing is addressed less 
systematically; I would say in approximately 50% of the cases. We know that this is a difficult 
theme, late relapses (up to 10 years post-initial Dx) are theoretically always possible, so the 
doctor has some restraint. We hesitate, we do not want to be called a liar by our patient later. 
It is clear that it is easier (safer) to talk about cure in certain diagnoses: Hodgkin, Burkitt, 
operated benign brain tumor (e.g. pilocytic astrocytoma of the posterior fossa) than in others 
(malignant brain tumor, metastatic neuroblastoma, other metastatic tumors, etc.). If the risk of 
having late effects is high (e.g. medulloblastoma), the physician will also be less likely to talk 
about healing than if he is weak (ALL). 
The timing of the announcement of a cure is somewhere between 5 and 10 years after the initial 
Dx, this may vary depending on it and certain other factors, also depending on the "psychology" 
of the patient or his parents and the relationship built over the years between the doctor and his 
patient / family. 
 
Moderator: 
Translation 
"It is not a case that we wait more than 5 years to tell a patient if he is cured. Most relapses occur 
during this time. Normally we also have more relapses for tumors of the nervous system. In cases 
where the prognosis is more pessimistic (tumor of the nervous system, sarcomas), a cure is not so 
frequently communicated. 
 
 
 
Forum thread C 
Third topic: Guidelines for communicating the cure 
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Do you know any guidelines (from a clinic, continuing education or publications) about sharing 
a cure? Do you stick to it? If so, why? If not, why not? 
 
Participant Physician #F3: 
No, I do not know any guidelines in this area. I don't think it's very useful to have any. In my 
opinion, the most important thing is that doctors have excellent training in news announcements 
and empathy. 
 
Participant Physician #F1: 
I don't know of any either, and I think it's impossible and probably useless to create. For the 
patient and his family, this announcement of a cure for the disease is certainly important and 
much awaited; on the other hand, they themselves often know very well that it is often not a 
complete cure and that a follow-up will be necessary, sometimes lifelong. For the doctor, to 
speak of a cure is to take a risk: to be mistaken or to mislead the patient, which is obviously 
difficult to live with. So, we often hesitate. 
The important thing is the clearest and most open dialogue  possible. Announce the cure of the 
cancer, yes, very likely, after ten years without relapse; but also have the courage to talk about 
potential long-term effects, to recommend follow-up when necessary, and follow the existing 
recommendations. In fact, continue the well-known strategy in oncology of open information, 
informed consent (here at long-term follow-up when it is needed or recommended). 
 
Moderator: 
Participant Physician # F2 Translation 
I do not know of any directive to communicate healing to a patient. 
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Supplementary Document 4: Additional results 
 
• Timing 
Many physicians told the patients that they were cured after a specific period of time had passed 
after diagnosis or end of therapy, most commonly five years after the end of therapy. Others 
chose a more flexible approach: 
“Situation: Routine follow-up visit five years after the end of therapy with, at this point in 
time, routine statement that the child is now ‘cured’ according to the official definition 
because a relapse is highly unlikely.” (Physician #8, male, older group) 
 “In fact, it is important for parents if I tell them that they can consider their child to having 
been cured three to five years - depending on diagnosis - after the end of therapy.” 
(Physician #3, male, older group) 
“The moment for younger children is clearly the end of therapy. […] Older children are 
more able to abstract that it is not over at the end [of therapy] but that one can only call it 
“cured” later.” (Physician #10, female, younger group) 
 
• Embedding of conversation on cure in clinical practice 
Only one physician mentioned how the conversation on cure is embedded in clinical practice:  
“Always one colleague in continuing education and mostly a nurse have to attend the 
discussion. Formal education on this topic takes place in a lecture and once per year in staff 
training. The nurse has to report the conversation in the regular rapport and note it in the 
journal in written form. And in the weekly rapport with the entire staff, the conversation has 
to be mentioned and discussed.” (Physician #1, male, older group) 
 
 
 
• Reactions of patients and parents 
Those physicians who used the term cure, reported that parents and patients were relieved when 
they received the message of having been cured. Some physicians reported that parents and 
patients eagerly awaited the message; others seemed to have considered to having been cured 
already before their physician told them: 
“You can feel the parents’ relief in those moments, even if not too much is being said about 
it [cure].” (Physician #3, male, older group) 
“Usually, [the message of cure] triggers a great happiness. The time of waiting is over at 
last.” (Physician #8, male, older group) 
 
• Misclassification 
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Two participants raised the concern that the survivors may have forgotten about the message of 
cure and that they classified themselves as being cured ignoring the exact question in the 
questionnaire. 
“Interpretation of background information [quantitative results]: I think the healthier and 
‘better-feeling’ the children feel after the end of therapy the more they think of themselves 
as being ‘cured’. Therefore, the lower proportion of cure in bone and brain tumours than in 
leukaemia and lymphoma is not that surprising.” (Physician #3, male, older group) 
“If the background information [quantitative results] says that 78% were told to be cured, 
this can be correct in their memory but does not have to be in accordance with the facts 
except if they received the message in written form.” (Physician #5, male, older group) 
“Doctors and patients probably define the term ‘cure’ differently (remaining disease-free vs. 
freedom of all tumour- and therapy-related bio-psycho-social health limitations). The 
numbers probably present a mixture of both concepts.” (Physician #13, male, younger 
group) 
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Supplementary Document 5: Quotes from physicians’ online focus groups 
 
Topic Quotes 
Helping 
survivors 
finish the 
cancer story 
“They finally get the chance to leave cancer behind.” (Physician #3, male, 
older group)  
“Perhaps, the patients do not address the topic of cure out of fear.” 
(Physician #12, female, younger group) 
“One reason for telling patients they are cured is to help them to lead as 
normal a life as possible without fear.” (Physician #13, male, younger 
group) 
“For me, the topic of cure is of great importance when in contact with 
patients, and because I realized over the years how important it is for 
children. […] It is important to talk about cure. Otherwise, a child will not 
understand the meaning of having undergone this nearly unbearable 
therapy.” (Physician #10, female, younger group) 
Late effects “[reason for] Not telling: if problems after the end of oncological therapy 
predominate in such a way that the cure from the oncological disease is no 
longer in the foreground, for example, independent living is no longer 
possible, or the daily routine is full of pain or disability.” (Physician #16, 
female, younger group) 
“Talking about cure would imply that follow-up care is not needed. 
However, this is not going to happen and parents feel that.” (Physician 
#15, female, younger group) 
“It is tricky to talk about cure in pediatric oncology given the possible late 
effects. […] If you talk about cure, patients and their relatives will have 
difficulty in understanding why continued follow-up care is necessary 
even after five years from treatment end.” (Physician #5, male, older 
group) 
“For me, late effects do not necessarily speak against talking about cure. 
That’s why the small proportion [who remembered the message of having 
been cured] in bone tumor survivors especially surprised me.” (Physician 
#10, female, younger group) 
Late relapse “Wishful thinking/optimism of a professional, his evaluation that it is 
more useful to ignore the very small probability of a relapse or the risk for 
future late effects than being statistically correct and mention every 
contingency no matter how unlikely.” (Physician #13, male, younger 
group) 
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“Possible reasons not to tell him/her that he/she is cured: The effort to be 
honest/correct knowing that there is still the possibility of a relapse.” 
(Physician #13, male, younger group) 
“The proportions of those informed that they were cured pretty much 
resemble the survival probabilities of the respective cancer types.” 
(Physician #1, male, older group) 
Case-by-case 
decisions 
“I do not have a standard approach, but choose my message individually 
and adapt it to the disease, the questions asked, and the parents’ 
communication style.” (Physician #17, male, younger group) 
“The message of cure depends on the disease and respective situation.” 
(Physician #3, male, older group) 
“How do you want to set up guidelines for a situation that is determined 
by so many factors and also changes at least from year to year? That 
should be a wasted effort.” (Physician #5, male, older group) 
Reluctance “I try to respond to the patients’ questions.” (Physician #16, female, 
younger group) 
“I always tried to avoid the word cure. I said, for example, that the child 
was doing fine after finishing the treatment and that we hoped it would 
remain that way.” (Physician #5, male, older group) 
“The term cure means the process of constitution or reconstitution of 
physical and mental integrity out of a burden or disease. In medicine, cure 
means the reconstitution of health and achievement of the original state. 
Therefore, it is fundamentally impossible to talk about cure in oncology, 
but instead about long-term survival and remission, with or without late 
effects.” (Physician #14, female, younger group) 
“The conversation during or at the end of the treatment includes the 
statement that one can assume cure after a period of 5 years. The patient or 
parents have already received the information and one assumes that it does 
not have to be repeated, especially because parents can remember it very 
well and do not need further information.” (Physician #2, female, older 
group) 
“Many parents and patients ask directly whether they are cured at a certain 
point in time.” (Physician #11, male, younger group) 
“I can remember one mother who has regularly asked whether her child is 
cured since the end of therapy (3 years ago, acute lymphoblastic leukemia) 
and really wants to know when this is.” (Physician #12, female, younger 
group) 
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Helping 
physicians 
resolve 
cognitive 
dissonance 
“Possible reasons not to tell him/her that he/she is cured: The effort to be 
honest/correct knowing that there is still the possibility of a relapse.” 
(Physician #13, male, younger group) 
 “Relatively soon after the rise in survival rates in the 1970s, we realized 
that it is delicate to speak of cure in pediatric oncology in view of the 
possible late effects. I therefore tried to avoid the word "healing" and said 
in each case, for example, that it was gratifying that the child was now 
well again despite discontinuation of therapy and that we hoped that this 
would now remain so.” (Physician #5, male, older group)  
“Reason to not communicate the healing could be one's own insecurity, 
possibly late consequences, which give the feeling that the patient is 
actually not healthy or actually that it is a non-healable tumour or even a 
benign tumour/residual tumour which persists and is observed.” (Physician 
#12, female, younger group)  
“Perhaps, they talk about cure in order to reassure over-anxious survivors 
or their relatives or to express that the patient can now again do anything 
of the same age. The more experienced an oncologist, the more cautious 
he will be: who knows what the future holds?” (Physician #5, male, older 
group) 
“And I certify the child's health. However, health is not the same as cured 
and parents rarely ask whether the child is "cured".” (Physician #15, 
female, younger group) 
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Supplementary Figure 1 
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